- Company
- Roche,set to establish a Korean precision medical ecosystem
- by jung, sae-im Mar 13, 2022 08:01pm
- Roche Korea announced on the 7th that it has signed term sheet with the KSMO to form a partnership with four organizations, including the KCSG, NCC, and the KHIDI, to establish a Korean precision medical ecosystem. Turnsheet is the process of specifying and agreeing on major contract conditions such as goals, scope of cooperation, roles and r
- Company
- Dong-A ST submitted an appeal against patent dispute
- by Kim, Jin-Gu Mar 13, 2022 07:59pm
- The battle over material patent of Forxiga (Dapagliflozin Propanediol Hydrate), an SGLT-2 inhibitor-based diabetes treatment, will head to the third round. The opportunity for Dong-A ST's generic for Forxiga to release is also expected to vary depending on when and how the Supreme Court decides. ◆ Dong-A ST, a letter of appeal was subm
- Company
- Sales of oral contraceptives rebound…4th gen Yaz sales up 2
- by Ji Yong Jun Mar 11, 2022 06:04am
- The oral contraceptive market grew greatly last year. Sales of the fourth-generation contraceptive Bayer Korea’s Yaz increased greatly, and the return of the third-generation Dong-A Pharmaceutical’s Mybora and the release of GC Pharm’s Dearmesoon had also contributed to market expansion. According to the market research institution IQVIA
- Company
- Global lead Humira’s sales drop... biosimilars occupy 16%
- by Chon, Seung-Hyun Mar 11, 2022 06:04am
- The &8361;200 billion autoimmune disease market has finally revealed its form in Korea. The growth of the global leading product ‘Humira’ had fallen somewhat due to the introduction of its biosimilars. The 5 biosimilars by domestic companies Celltrion, Samsung Bioepis, LG Chem, etc. are also increasing their influence in the market, but their
- Company
- MSD’s 15-valent vaccine ‘Vaxneuvance’ comes to Korea
- by Eo, Yun-Ho Mar 10, 2022 05:54am
- MSD aims to challenge the dominance of ‘Prevenar 13’ in the domestic pneumococcal vaccine market. According to industry sources, MSD Korea has submitted an application and is being reviewed for the marketing authorization of its 15-valent pneumococcal vaccine ‘Vaxneuvance,' and may be approved within the year. If released, Vaxneuv
- Company
- The sales of Prolia & Evenity exceed ₩100 billion
- by Mar 10, 2022 05:53am
- Amgen has opened an era of 100 billion won in the osteoporosis treatment market. Sales of the two products are increasing rapidly as sequential treatments leading to Evenity-Prolia are being put forward. According to IQVIA, a pharmaceutical research institute, sales of Amgen's osteoporosis treatment, Denosumab, stood at 92.1 billion won last
- Company
- Why the Patent Court rejected the ‘prodrug strategy’
- by Kim, Jin-Gu Mar 10, 2022 05:53am
- Dong-A ST is challenging the substance patent of AstraZeneca’s SGLT-2 inhibitor antidiabetic treatment ‘Forxiga (dapagliflozin).’ The industry’s eyes are focused on Dong-A ST’s challenge, with the expectation that Dong-A ST’s success would bring a new strategy that can overcome the substance patent of originals. However, Dong-A
- Company
- Keytruda for esophageal cancer indications is imminent
- by Eo, Yun-Ho Mar 8, 2022 06:08am
- Keytruda, an immuno-cancer drug, is expected to be able to be prescribed for esophageal cancer. According to related industries, the MFDS has finally reviewed the first round of local progressive or metastatic esophageal cancer (GEJ), in which PD-1 inhibitory immuno-cancer drug Keytruda (Pembrolizumab) of MSD is non-resectable. Permission is
- Company
- Generation shift of ALK targeted drugs... rise of Alecensa
- by Mar 8, 2022 06:08am
- The targeted cancer therapy market for patients with ALK mutations has been restructured around second-generation drugs. The share of the first-generation drug Xalkori, which used to occupy 2/3 of the market fell to 20%, and the representative second-generation drug ‘Alecensa' took over the market. However, Alunbrig, a latecomer into the second
- Company
- Domestic production of Sputnik V was delayed
- by Kim, Jin-Gu Mar 8, 2022 06:08am
- Due to the war between Russia and Ukraine, shipments of domestic companies that consignment produce the COVID-19 vaccine Koruspharm developed by Russia are also being postponed indefinitely. Koruspharm said in a telephone interview with Dailypharm on the 4th, "We are continuously talking to the Russian side via e-mail or phone call even af
